Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS 2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors

20 Nov 2018

Abstract excerpt

Testicular germ cell tumours (GCTs) mostly affect young men at age 17-40. Although high cure rates can be achieved by orchiectomy and chemotherapy, GCTs can still be a lethal threat to young patients with metastases or therapy resistance. Thus, alternative treatment options are needed. Based on studies utilising GCT cell lines, the histone deacetylase inhibitor romidepsin is a promising therapeutic option,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Testicular diseases and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30460772
DOI: 10.1111/jcmm.13971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS 2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectorsPMID 30460772Read ↗

A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatmentSemantic proximity Read ↗

Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insightsSemantic proximity Read ↗

Epigenetic treatment combinations to effectively target cisplatin‐resistant germ cell tumors: past, present, and future considerationsSemantic proximity Read ↗

Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overviewSemantic proximity Read ↗

Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumoursSemantic proximity Read ↗

Differential gene expression in cisplatin-resistant and -sensitive testicular germ cell tumor cell linesSemantic proximity Read ↗

Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell TumorsSemantic proximity Read ↗

SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axisSemantic proximity Read ↗

Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6BSemantic proximity Read ↗

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabineSemantic proximity Read ↗

Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathwaySemantic proximity Read ↗

Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.